Skeletal muscle: a brief review of structure and function, Calcif Tissue Int, vol.96, pp.183-95, 2015. ,
Muscular dystrophies, Clin Chest Med, vol.39, pp.377-89, 2018. ,
Gene therapy for muscular dystrophy: moving the field forward, Pediatr Neurol, vol.51, pp.607-625, 2014. ,
Cas-based methods for genome engineering, Trends Biotechnol, vol.31, pp.397-405, 2013. ,
Crystal structure of Cas9 in complex with guide RNA and target DNA, Cell, vol.156, pp.935-984, 2014. ,
CRISPR-Cas9 Structures and Mechanisms, Annu Rev Biophys, vol.46, pp.505-534, 2017. ,
Off-target effects in CRISPR/Cas9-mediated genome engineering, Mol Ther Nucleic Acids, vol.4, p.264, 2015. ,
CRISPR/Cas9 can mediate highefficiency off-target mutations in mice in vivo, Cell Death Dis, vol.9, p.1099, 2018. ,
Rapid and efficient gene deletion by CRISPR/Cas9, Methods Mol Biol, pp.233-280, 1961. ,
CRISPR correction of Duchenne muscular dystrophy, Annu Rev Med, vol.70, pp.239-55, 2019. ,
Therapeutic genome editing for myotonic dystrophy type 1 using CRISPR/Cas9, Mol Ther, vol.26, pp.2617-2647, 2018. ,
Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA, Science, vol.345, pp.1184-1192, 2014. ,
Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy, Nat Commun, vol.8, p.14454, 2017. ,
CRISPR/Cas9-based dystrophin restoration reveals a novel role for dystrophin in bioenergetics and stress resistance of muscle Pprogenitors, Stem Cells, vol.37, pp.1615-1643, 2019. ,
Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies, Expert Rev Mol Med, vol.21, p.5, 2019. ,
Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy, Nat Biotechnol, vol.36, pp.536-545, 2018. ,
Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole utrophin modulator, following singleand multiple-dose administration to pediatric patients with Duchenne muscular dystrophy, PLoS One, vol.11, p.152840, 2016. ,
High levels of AAV vector integration into CRISPR-induced DNA breaks, Nat Commun, vol.10, p.4439, 2019. ,
Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins, RNA, vol.25, pp.1421-1452, 2019. ,
CRISPR correction of Duchenne muscular dystrophy, Annu Rev Med, vol.70, pp.239-55, 2019. ,
In dogs, CRISPR fixes a muscular dystrophy, Science, vol.361, p.835, 2018. ,
Immunity to CRISPR-Cas9, Sci Transl Med, vol.1, p.5328, 2019. ,
Cas9 immunity creates challenges for CRISPR gene editing therapies, Nat Commun, vol.9, p.3497, 2018. ,
Identification of preexisting adaptative immunity to Cas9 proteins in humans, Nat Med, vol.25, pp.249-54, 2019. ,
Gene and cell doping: the new frontier. Beyond myth or reality, Med Sport Sci, vol.62, pp.91-106, 2017. ,
Myostatin mutation associated with gross muscle hypertrophy in a child, N Engl J Med, vol.350, pp.2682-2690, 2004. ,
Intégration des vecteurs AAV et mutagenèse insertionnelle, Med Sci (Paris), vol.32, pp.167-74, 2016. ,
Biologie et médecine « do-it-yourself ». Histoire, pratiques, enjeux, Med Sci, vol.34, pp.473-482, 2018. ,
Cellular reprogramming, genome editing, and alternative CRISPR Cas9 technologies for precise gene therapy of Duchenne muscular dystrophy, Stem Cells Int, vol.8765154, 2017. ,
A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing, Nat Nanotechnol, vol.14, pp.974-80, 2019. ,
Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair, Nat Biomed Eng, vol.1, pp.889-901, 2017. ,
In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease, F1000Res, vol.6, p.2153, 2017. ,
Generation of muscular dystrophy model rats with a CRISPR/ Cas system, Sci Rep, vol.4, p.5635, 2014. ,
Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy, Sci Transl Med, vol.9, 2017. ,
A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9, Dis Model Mech, vol.11, 2018. ,
Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9, Hum Mol Genet, vol.24, pp.3764-74, 2015. ,
A gene-edited mouse model of Limb-Girdle muscular dystrophy 2C for testing exon skipping, Dis Model Mech, vol.13, p.40832, 2019. ,
Mouse model of severe recessive RYR1-related myopathy, Hum Mol Genet, vol.28, pp.3024-3060, 2019. ,
In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse, Nat Commun, vol.10, p.4537, 2019. ,
Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy, Science, vol.362, pp.86-91, 2018. ,
Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy, Science, vol.351, pp.400-403, 2016. ,
Restoration of dystrophin protein expression by exon skipping utilizing CRISPR-Cas9 in myoblasts derived from DMD patient iPS cells, Methods Mol Biol, vol.1828, pp.191-217, 2018. ,
Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing, Sci Adv, vol.4, p.9004, 2018. ,
CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo, Mol Ther, vol.26, pp.2604-2620, 2018. ,
AAV9 edits muscle stem cells in normal and dystrophic adult mice, Mol Ther, vol.27, pp.1568-85, 2019. ,
In vivo gene editing in dystrophic mouse muscle and muscle stem cells, Science, vol.351, pp.407-418, 2016. ,
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy, Science, vol.351, pp.403-410, 2016. ,
Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells, Nucleic Acids Res, vol.46, pp.8275-98, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02357315
Genome editing of expanded CTG repeats within the human DMPK gene reduces nuclear RNA foci in muscle of DM1 mice, Mol Ther, vol.27, pp.1372-88, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02177548
Gene correction of LGMD2A patient-specific iPSCs for the development of targeted autologous cell therapy, Mol Ther, vol.27, pp.2147-57, 2019. ,